NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) Director R Scott Huennekens purchased 12,500 shares of the company's stock in a transaction that occurred on Wednesday, November 18th. The shares were purchased at an average price of $8.29 per share, for a total transaction of $103,625.00. Following the transaction, the director owned 12,500 shares of the company's stock, valued at $103,625. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
NeuroPace Price Performance
NPCE traded up $0.02 on Wednesday, reaching $8.22. 307,333 shares of the company's stock were exchanged, compared to its average volume of 219,548. The stock has a market cap of $283.18 million, a PE ratio of -14.68 and a beta of 1.98. The stock's fifty day moving average price is $12.94 and its 200-day moving average price is $14.67. NeuroPace, Inc. has a twelve month low of $5.46 and a twelve month high of $19.60. The company has a debt-to-equity ratio of 5.15, a current ratio of 5.26 and a quick ratio of 4.09.
More NeuroPace News
These are some of the NPCE news items that stood out recently:
- Neutral Sentiment: One brokerage report cited an average price target of $20.50, implying substantial potential upside from recent levels, although that figure may not reflect the latest target cuts. Brokerage price target report
- Negative Sentiment: Analyst sentiment has weakened: Wolfe Research downgraded NPCE to Hold, while JPMorgan and Wells Fargo cut their ratings and reduced price targets to $9. HC Wainwright lowered its target to $12 but retained a Buy rating. Analyst ratings and targets
- Negative Sentiment: A Zacks analysis pointed to weak implant activity, execution challenges and regulatory risks as concerns for NeuroPace, despite the company’s growth potential and discounted valuation. Zacks analysis
Institutional Investors Weigh In On NeuroPace
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in NeuroPace during the second quarter valued at approximately $39,369,000. GSA Capital Partners LLP purchased a new stake in NeuroPace during the second quarter worth approximately $1,836,000. First Light Asset Management LLC increased its position in shares of NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company's stock worth $45,464,000 after acquiring an additional 401,201 shares in the last quarter. Deutsche Bank AG acquired a new stake in shares of NeuroPace in the second quarter worth $14,919,000. Finally, Man Group plc acquired a new stake in shares of NeuroPace in the second quarter worth $1,336,000. Hedge funds and other institutional investors own 78.83% of the company's stock.
Analyst Ratings Changes
A number of brokerages recently weighed in on NPCE. Wolfe Research cut shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Monday. Guggenheim reaffirmed a "neutral" rating on shares of NeuroPace in a report on Wednesday, July 29th. Raymond James Financial set a $21.00 price target on NeuroPace in a research report on Tuesday, September 15th. Wall Street Zen downgraded NeuroPace from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, KeyCorp decreased their price objective on NeuroPace from $18.00 to $14.00 and set an "overweight" rating for the company in a research report on Friday, November 13th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NeuroPace currently has an average rating of "Hold" and a consensus price target of $13.11.
Get Our Latest Analysis on NPCE
About NeuroPace
(
Get Free Report)
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.